Sugi Predict

Sugi Predict / Compounds / SCHEMBL2476965

SCHEMBL2476965

SCHEMBL2476965

N#Cc1cc(F)c(N)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KHK P50053 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.46
▸ TRPV4 Q9HBA0 3/20 0.41
▸ GAA P10253 1/20 0.39
▸ CYP11B2 P19099 5/20 0.38
▸ CYP2D6 P10635 2/20 0.35
▸ SLC6A2 P23975 2/20 0.35
▸ SLC6A4 P31645 2/20 0.35
▸ NOS2 P35228 2/20 0.35
▸ PGK1 P00558 1/20 0.35
▸ VCAM1 P19320 1/20 0.34
▸ AR P10275 1/20 0.34
▸ CYP11B1 P15538 3/20 0.33
▸ CSNK1A1 P48729 1/20 0.33
▸ CLK4 Q9HAZ1 1/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ CD44 P16070 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17559551 0.92 KHK (0.47) KHKALDH1A1TRPV4GAACYP11B2
SCHEMBL14358481 0.83 KHK (0.52) KHKALDH1A1TRPV4GAACYP11B2
SCHEMBL3336692 0.82 ALDH1A1 (0.51) KHKALDH1A1TRPV4CYP11B2CYP2D6
SCHEMBL1291792 0.82 GAA (0.46) KHKALDH1A1TRPV4GAACYP11B2
SCHEMBL13660126 0.82 KHK (0.48) KHKALDH1A1TRPV4GAACYP11B2
SCHEMBL6661759 0.80 KHK (0.47) KHKALDH1A1TRPV4GAACYP11B2
SCHEMBL7073779 0.80 GAA (0.57) KHKALDH1A1TRPV4GAACYP11B2
SCHEMBL7575800 0.80 ALDH1A1 (0.50) KHKALDH1A1TRPV4CYP11B2CYP2D6
SCHEMBL10947192 0.80 TRPV4 (0.56) KHKALDH1A1TRPV4CYP11B2CYP2D6
SCHEMBL30110369 0.80 ALDH1A1 (0.50) KHKALDH1A1TRPV4CYP11B2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240299385-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS REWIND THERAPEUTICS NV (BE) 2024-09-12 — — US disclosed
EP-4347558-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS ReWind Therapeutics NV (BE) 2024-04-10 — — EP disclosed
CN-117794898-A 3-pyrrolylsulfonamide compounds as GPR17 antagonists 瑞文德医疗公众有限公司 2024-03-29 — — CN disclosed
US-11919921-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2024-03-05 — — US disclosed
WO-2022254027-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS REWIND THERAPEUTICS NV (BE) 2022-12-08 — — WO disclosed
US-20220289783-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2022-09-15 — — US disclosed
US-11377464-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2022-07-05 — — US disclosed
WO-2022011274-A1 SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 GOLDFINCH BIO, INC. (US) 2022-01-13 — — WO disclosed
WO-2022011274-A1 SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 GOLDFINCH BIO, INC. (US) 2022-01-13 — — WO disclosed
CN-113621005-A alpha-D-galactoside inhibitors of galectins 格莱克特生物技术公司 2021-11-09 — — CN disclosed
US-20170253591-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-07 — — US disclosed
EP-3192791-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-07-19 — — EP disclosed
WO-2017004609-A1 THIADIAZOLE MODULATORS OF S1P AND METHODS OF MAKING AND USING EXELIXIS, INC. (US) 2017-01-05 — — WO disclosed
WO-2017004609-A1 THIADIAZOLE MODULATORS OF S1P AND METHODS OF MAKING AND USING EXELIXIS, INC. (US) 2017-01-05 — — WO disclosed
WO-2016120403-A1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS GALECTO BIOTECH AB (DK) 2016-08-04 — — WO disclosed
EP-2370438-A1 IMIDAZO [1,2A]PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION Exelixis, Inc. (US) 2011-10-05 — — EP disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 — — US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 — — US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 — — WO disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377464-B2 Galactoside inhibitor of galectins LGALS3, LGALS1, LGALS2 KHK 2505/4885ALDH1A1 1974/4885TRPV4 3248/4885
US-11919921-B2 Galactoside inhibitor of galectins LGALS3, LGALS1, LGALS2 KHK 2505/4885ALDH1A1 1974/4885TRPV4 3248/4885
US-20220289783-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS LGALS1, LGALS3, LGALS2 KHK 2774/4885ALDH1A1 1785/4885TRPV4 3291/4885
US-20240299385-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS GPR3, GPR27, GPR65 KHK 4273/4885ALDH1A1 3504/4885TRPV4 149/4885
US-20170253591-A1 HETEROCYCLIC COMPOUND RORC, RORB, RORA KHK 4704/4885ALDH1A1 756/4885TRPV4 2025/4885
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 KHK 2205/4885ALDH1A1 1246/4885TRPV4 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.